Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316145 | 0.80 | EDNRA (0.35) | OPRK1ALDH1A1EDNRAMAPK1CYP2C19 | |
| SCHEMBL5250509 | 0.79 | ALDH1A1 (0.37) | KMT2AALDH1A1RECQLMAPK1SLC9A1 | |
| SCHEMBL1119643 | 0.78 | THRB (0.35) | OPRK1EDNRAMAPK1CYP2C19HDAC4 | |
| SCHEMBL5390121 | 0.78 | CHRNA7 (0.33) | RECQLCA2 | |
| SCHEMBL7985531 | 0.77 | HTR2C (0.32) | MEN1KMT2ARECQLLMNACYP2C19 | |
| SCHEMBL4608630 | 0.77 | AKR1C3 (0.34) | ALDH1A1EDNRAMAPTCYP2C19SLC9A1 | |
| SCHEMBL4371618 | 0.77 | SLC9A1 (0.36) | OPRK1ALDH1A1EDNRAMAPK1CYP2C19 | |
| SCHEMBL2508140 | 0.77 | HTR2A (0.35) | OPRK1MEN1KMT2AALDH1A1RECQL | |
| SCHEMBL2121106 | 0.77 | KDM1A (0.34) | ALDH1A1EDNRAMAPK1CYP2C19SLC9A1 | |
| SCHEMBL6601729 | 0.77 | HTR2A (0.35) | OPRK1MEN1KMT2AALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772291-B2 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| EP-1534280-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
| WO-1998006688-A1 | CATALYSED COUPLING OF ARYL MAGNESIUM HALOGENIDES AND BROMARYL CARBOXYLIC ACID COMPOUNDS FOR PREPARING BIPHENYL CARBOXYLIC ACIDS | GREAT LAKES CHEMICAL KONSTANZ GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | GRIN2C, CHAT, COMT | GRM1 64/4885GRM2 29/4885GRM4 47/4885 |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | LDLR, NR1H2, NR1H3 | GRM1 2045/4885GRM2 1887/4885GRM4 1771/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | GRM1 512/4885GRM2 484/4885GRM4 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.